KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Goodwill (2016 - 2025)

Historic Goodwill for Pacira BioSciences (PCRX) over the last 14 years, with Q3 2025 value amounting to $20.3 million.

  • Pacira BioSciences' Goodwill changed N/A to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $163.2 million for FY2023, which is 0.0% changed from last year.
  • As of Q3 2025, Pacira BioSciences' Goodwill stood at $20.3 million.
  • Over the past 5 years, Pacira BioSciences' Goodwill peaked at $163.2 million during Q4 2022, and registered a low of $20.3 million during Q2 2025.
  • For the 5-year period, Pacira BioSciences' Goodwill averaged around $123.4 million, with its median value being $146.1 million (2022).
  • Its Goodwill has fluctuated over the past 5 years, first skyrocketed by 5811.63% in 2022, then plummeted by 8756.46% in 2025.
  • Over the past 5 years, Pacira BioSciences' Goodwill (Quarter) stood at $145.2 million in 2021, then rose by 12.43% to $163.2 million in 2022, then changed by 0.0% to $163.2 million in 2023, then changed by 0.0% to $163.2 million in 2024, then plummeted by 87.55% to $20.3 million in 2025.
  • Its Goodwill was $20.3 million in Q3 2025, compared to $20.3 million in Q2 2025 and $21.5 million in Q1 2025.